Showing 3491-3500 of 5062 results for "".
Patient Perspectives on Unmet Needs in Topical Psoriasis Therapy
https://practicaldermatology.com/issues/january-february-2025/patient-perspectives-on-unmet-needs-in-topical-psoriasis-therapy/32972/Despite the advantages of topical treatment, nonadherence (including overuse and underuse) affects up to 50% of patients, and therapy overuse is often incited by the desire for rapid clearance, ineffectiveness, and unclear instructions.DermWire TV: Positive Data on UCB's Bimekizumab in HS patients; CSF takes Nashville by Storm; Rocatinlimab Performs Well in AD
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-positive-data-on-ucbs-bimekizumab-hs-patients-csf-takes-nashville-by-storm-rocatinlimab-performs-well-in-ad/20159/Bimekizumab performs well in Hidradenitis Suppurativa patients, Cosmetic Surgery Forum takes Nashville by storm, and Rocatinlimab—a novel monoclonal antibody therapy—shows promise in atopic dermatitis are the stories topping the news in this episode of DermWireTV.DermWireTV: Medicare Cuts; Revision, Alastin, Obagi Acquisitions; CSF Hits Nashville
https://practicaldermatology.com/topics/practice-management/dermwiretv-medicare-cuts-revision-alastin-obagi-acquisitions-csf-hits-nashville/20033/Congress is working to avert a potential pay cut for physicians who treat Medicare patients, and a bipartisan solution has been introduced. Cuts loom as the AMA has released data showing that Medicare claims data exclusive to physician services fell an estimated $13.9 billion or 14 percent below expPsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Treatment Considerations for Hyperpigmentation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/treatment-considerations-for-hyperpigmentation/18830/Seemal R. Desai, MD and Marta I. Rendon, MD discuss their treatment protocols for hyperpigmentation—from prescriptions and cosmeceuticals to lasers and peels. Noting that hyperpigmentation is a chronic, life-long condition, they emphasize the importance of vehicle consideration in enhancing efficacyCoding for Superficial Radiation Therapy
https://practicaldermatology.com/videos/c-suite-chats/coding-for-superficial-radiation-therapy/56364/Joseph C. Sardano, Chairman and CEO of Sensus Healthcare, discusses the issue of insurance denials for noninvasive skin cancer treatments such as superficial radiation therapy (SRT), and a new solution for ensuring predictable payment.An Exciting Year in Dermatology
https://practicaldermatology.com/topics/psoriasis/an-exciting-year-in-dermatology/19929/From new topicals to novel systemic agents, several treatments may be coming to the market in the next two years, while existing therapies may see label expansions. Bruce Strober, MD, PhD offers a look at new MOAs and the evidence for their use.Is it time to consider telemedicine at your dermatology practice?
https://practicaldermatology.com/topics/practice-management/is-it-time-to-consider-telemedicine-at-your-dermatology-practice/19779/Telemedicine is in high demand, now more than ever. This Ekwa Marketing video explores how well it fits with dermatology practices, and what it takes to implement it.Eczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?